D
Diana V. Do
Researcher at Stanford University
Publications - 279
Citations - 10679
Diana V. Do is an academic researcher from Stanford University. The author has contributed to research in topics: Ranibizumab & Macular edema. The author has an hindex of 44, co-authored 258 publications receiving 9057 citations. Previous affiliations of Diana V. Do include University of Nebraska Medical Center & Johns Hopkins University.
Papers
More filters
Journal ArticleDOI
Intravitreal aflibercept for diabetic macular edema.
Jean-François Korobelnik,Diana V. Do,Ursula Schmidt-Erfurth,David S. Boyer,Frank G. Holz,Jeffrey S. Heier,Edoardo Midena,Peter K. Kaiser,Hiroko Terasaki,Dennis M. Marcus,Quan Dong Nguyen,Glenn J. Jaffe,Jason S. Slakter,Christian Simader,Yuhwen Soo,Thomas Schmelter,George D. Yancopoulos,Neil Stahl,Robert Vitti,Alyson J. Berliner,Oliver Zeitz,Carola Metzig,David M. Brown +22 more
TL;DR: Overall incidences of ocular and nonocular adverse events and serious adverse events, including the Anti-Platelet Trialists' Collaboration-defined arterial thromboembolic events and vascular deaths, were similar across treatment groups, and IAI was well-tolerated.
Journal ArticleDOI
Two-Year Outcomes of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study
Quan Dong Nguyen,Syed Mahmood Shah,Syed Mahmood Shah,Afsheen Khwaja,Roomasa Channa,Elham Hatef,Diana V. Do,David S. Boyer,Jeffery S. Heier,Prema Abraham,Allen B. Thach,Eugene S. Lit,Bradley S. Foster,Erik Kruger,Pravin U. Dugel,Thomas S.K. Chang,Arup Das,Thomas A. Ciulla,John S. Pollack,Jennifer I. Lim,Dean Eliot,Peter A. Campochiaro +21 more
TL;DR: Intraocular injections of RBZ provided benefit for patients with DME for at least 2 years, and when combined with focal or grid laser treatments, the amount of residual edema was reduced, as were the frequency of injections needed to control edema.
Journal ArticleDOI
Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies.
David M. Brown,Ursula Schmidt-Erfurth,Diana V. Do,Frank G. Holz,David S. Boyer,Edoardo Midena,Jeffrey S. Heier,Hiroko Terasaki,Peter K. Kaiser,Dennis M. Marcus,Quan Dong Nguyen,Glenn J. Jaffe,Jason S. Slakter,Christian Simader,Yuhwen Soo,Thomas Schmelter,George D. Yancopoulos,Neil Stahl,Robert Vitti,Alyson J. Berliner,Oliver Zeitz,Oliver Zeitz,Carola Metzig,Jean-François Korobelnik +23 more
TL;DR: In both VISTA and VIVID, the 52-week visual and anatomic superiority of IAI over laser control was sustained through week 100, with similar efficacy in the 2q4 and 2q8 groups.
Journal ArticleDOI
Vascular Endothelial Growth Factor Is a Critical Stimulus for Diabetic Macular Edema
Quan Dong Nguyen,S. Tatlipinar,Syed Mahmood Shah,Julia A. Haller,Edward Quinlan,Jennifer U. Sung,Ingrid Zimmer-Galler,Diana V. Do,Peter A. Campochiaro +8 more
TL;DR: Intraocular injections of ranibizumab significantly reduced foveal thickness and improved visual acuity in 10 patients with DME, which demonstrated that VEGF is an important therapeutic target for DME.
Journal ArticleDOI
Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study
Quan Dong Nguyen,Syed Mahmood Shah,Syed Mahmood Shah,Jeffery S. Heier,Diana V. Do,Jennifer I. Lim,David S. Boyer,Prema Abraham,Peter A. Campochiaro +8 more
TL;DR: During a span of 6 months, ranibizumab injections by the current protocol had a significantly better visual outcome than focal/grid laser treatment in patients with DME.